Endocrinology, Vol 117, 690-697, Copyright © 1985 by Endocrine Society

ARTICLES

The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form

SR George, M Watanabe, T Di Paolo, P Falardeau, F Labrie and P Seeman

In order to determine whether the high affinity state or the low affinity state of the dopamine receptor mediated the inhibition of release of PRL by dopamine agonists, a large number of dopaminergic agonists (n = 31) and antagonists (n = 24) were tested for their potencies to inhibit the binding of [3H] spiperone to porcine anterior pituitary tissue, and for their potencies to affect the release of PRL from rat anterior pituitary cells in culture. All agonists (except bromocriptine, ergocryptine, and dihydroergocryptine) inhibited [3H]spiperone binding in two phases: one phase occurred at nanomolar or subnanomolar concentrations (representing the high affinity state of the dopamine receptor) and the other phase occurred at much higher concentrations of agonist (the low affinity state of the dopamine receptor). The dissociation constants (K) for each drug at each state were derived by computer, with the program LIGAND. It was observed that the agonist K values for the high affinity state were virtually identical with those agonist concentrations inhibiting PRL release; the K values for the low affinity state were about 2 orders higher. These data suggest that the high affinity state of the D2 dopamine receptor is the functional state which mediates the inhibition of PRL release.

This article has been cited by other articles:

				P. Seeman, D. Weinshenker, R. Quirion, L. K. Srivastava, S. K. Bhardwaj, D. K. Grandy, R. T. Premont, T. D. Sotnikova, P. Boksa, M. El-Ghundi, et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis PNAS, March 1, 2005; 102(9): 3513 - 3518. [Abstract] [Full Text] [PDF]

				P. Seeman Comment on "Diverse Psychotomimetics Act Through a Common Signaling Pathway" Science, July 9, 2004; 305(5681): 180c - 180c. [Full Text] [PDF]

				D.-R. Hwang, R. Narendran, Y. Huang, M. Slifstein, P. S. Talbot, Y. Sudo, B. N. Van Berckel, L. S. Kegeles, D. Martinez, and M. Laruelle Quantitative Analysis of (-)-N-11C-Propyl-Norapomorphine In Vivo Binding in Nonhuman Primates J. Nucl. Med., February 1, 2004; 45(2): 338 - 346. [Abstract] [Full Text] [PDF]

				P. Seeman Atypical Antipsychotics: Mechanism of Action Focus, January 1, 2004; 2(1): 48 - 58. [Abstract] [Full Text] [PDF]

				S. M. Weiss, E. Whawell, R. Upton, and C. T. Dourish Potential for antipsychotic and psychotomimetic effects of A2A receptor modulation Neurology, December 9, 2003; 61(90116): S88 - 93. [Abstract] [Full Text]